Compare Lowe`s Companies Inc (LOW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Twist Bioscience Corp — how do they compare? Lowe`s Companies Inc trades at $205 (market cap $114.78B), while Twist Bioscience Corp trades at $88.43 (market cap $5.45B). The key difference: Lowe`s Companies Inc is far larger — about 21.1× Twist Bioscience Corp's market cap, and Lowe`s Companies Inc pays a 2.44% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| LOW | TWST | |
|---|---|---|
Market Cap | $114.78B | $5.45B |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $102.88 |
52-Week Low | $204.76 | $24.16 |
Enterprise Value | $156.54B | $5.37B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $204.08, down 2.23% on the day, amid a bearish technical signal. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $3.03 exceeding the $2.97 estimate. Revenue for 2025 was $83.67 billion, with a net income margin of 7.51%. The company maintains a strong dividend history, recently declaring a $1.25 per share dividend payable in August 2026.
The outlook is mixed. Strong analyst consensus, with a $260.88 price target and 60.79% buy ratings, suggests upside potential. However, high debt levels, with a debt-to-asset ratio of 82.33% for 2025, and a projected net cash flow deficit of $2.3 billion for 2026 present significant financial risks. Competitive pressures in the home improvement sector remain a key challenge.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
